Skip to content
Company Analysis

Cryo-Cell International, Inc. CCEL

A comprehensive view of key metrics, scores, and financial health for Cryo-Cell International, Inc.

Overview of Cryo-Cell International, Inc.

CCEL ASE
Healthcare Medical Care Facilities Framework: General Corporate Micro Cap
Cryo-Cell International, Inc. (CCEL), is a Micro Cap company, in the Medical Care Facilities industry, last closed at $3.56, about 82.3% undervalued vs fair value, -30.1% 1Y return, ranked 1033/1122 in sector.
Metrics Rev Growth -1.3% ROE 15.3% Gross Margin 76.6% Div Yield 12.23%
USD 3.56
-1.93%
(Delayed)
• Vol 90d: 60.9%
52-Week Range
Market Cap
$29.20M
Enterprise Value
$32.09M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Good
Valuation
Weak
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Good
Valuation
Weak
Completeness: 82%
Confidence: 88%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://www.cryo-cell.com
HQ Oldsmar, FL
Employees 82
Fiscal year Nov 30

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$6
$6
$7
Current: $3.56 +82% vs base

Engine Room Money Flow™

Micro Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$31.6M
-1.3%%
Gross Profit
$24.2M
0.6%%
Operating Income
$482.4K
-87.3%%
Net Income
$-2.4M
-704.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
-99.1%
Poor

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$3.4M
143.1% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
5
Active Leaks
4/5
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Cryo-Cell International, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
51
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
60
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing CCEL's balance between Growth (31.5%), Profitability (38.7%), and Safety (29.9%). Growth 31% Safety 30% Profitability 39%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

41th percentile vs peers
41
Key Signals
EPS Growth YoY 1.04 88p Rev Growth YoY -1.3% 35p Revenue CAGR 3Y 1.3% 39p TSR -32.9% 19p EPS CAGR 3Y -41.4% 7p
Strengths
  • EPS Growth YoY in top 20% of peers (1.04, 88th percentile)
  • Superior capital returns - 2 return metrics above peer median
  • Gross Profit Margin in top 20% of peers (76.6%, 93th percentile)
  • FCF Margin in top 20% of peers (16.6%, 88th percentile)
  • Cash Flow to Debt Ratio in top 20% of peers (2.46, 87th percentile)
Risks

No significant risks identified for this axis.

Profitability

50th percentile vs peers
51
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

39th percentile vs peers
39
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Cryo-Cell International, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$6.49
- - -
+82.3% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000